A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 [everolimus] as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-Endocrine Tumors
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- Acronyms RAMSETE
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 27 Feb 2017 Status changed from discontinued to completed.
- 25 Jan 2017 This trial has been completed in Italy as per European Clinical Trials Database record.